Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapy
Phase of Trial: Phase I/II
Latest Information Update: 30 Jan 2017
Price : $35 *
At a glance
- Drugs Resminostat (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Yakult Honsha
- 30 Jan 2017 Primary endpoint (Progression-free survival) has not been met.
- 30 Jan 2017 Results published in the Investigational New Drugs
- 11 Jul 2016 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.